WESPAC Advisors LLC Acquires 7,248 Shares of Gilead Sciences, Inc. $GILD

WESPAC Advisors LLC raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 322.6% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 9,495 shares of the biopharmaceutical company’s stock after purchasing an additional 7,248 shares during the quarter. WESPAC Advisors LLC’s holdings in Gilead Sciences were worth $1,053,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Smallwood Wealth Investment Management LLC bought a new stake in Gilead Sciences in the first quarter valued at approximately $25,000. Activest Wealth Management raised its stake in Gilead Sciences by 2,837.5% in the first quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. Goodman Advisory Group LLC bought a new stake in Gilead Sciences in the first quarter valued at approximately $29,000. Colonial Trust Advisors raised its stake in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 213 shares during the period. Finally, Core Alternative Capital raised its stake in Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 241 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on GILD. UBS Group upped their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a research note on Saturday, September 27th. Royal Bank Of Canada increased their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a “sector perform” rating in a research note on Friday, August 8th. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 16th. Finally, Truist Financial upgraded Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Three research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $117.17.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the sale, the chief executive officer owned 591,203 shares of the company’s stock, valued at $66,013,726.98. This represents a 1.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the sale, the chief financial officer directly owned 159,555 shares in the company, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock valued at $9,402,130 over the last 90 days. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Trading Up 2.8%

Shares of NASDAQ:GILD opened at $116.78 on Wednesday. The company has a market capitalization of $144.90 billion, a P/E ratio of 23.26, a P/E/G ratio of 0.77 and a beta of 0.34. Gilead Sciences, Inc. has a 1 year low of $84.17 and a 1 year high of $121.83. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The business’s 50 day simple moving average is $114.41 and its 200 day simple moving average is $110.06.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s quarterly revenue was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.